Background: Tailoring therapy is the target in the management of any cancer; if factors which can predict response to treatment are identified, we can individualize treatment. Locally advanced rectal cancer studies reported that tumor microenvironment and host immune response played roles in sensitivity to chemoradiotherapy (CRT) by proving that both peripheral circulating lymphocytes and tumor infiltrating lymphocytes (TILs) strongly correlated with the response rate to CRT and it impacted disease outcome. Aim of the work: We aimed to assess the predictive value of peripheral blood lymphocytes and tumor infiltrating lymphocytes by correlation with regression rate post chemo-radiotherapy in patients with rectal cancer, and to find correlation between peripheral and tissue lymphocytes. Method: Before neoadjuvant, CRT venous blood samples were obtained from 40 patients with rectal cancer, and prior to surgery. Blood cell counts in the samples were analyzed using an au- 
Introduction
Although the last years show much improvement in the plan of management for patients with locally advanced rectal cancer which results in improved outcomes, rectal cancer is still one of the leading causes of cancer related death [1] . Tailoring therapy has become the aim in treatment plan of any cancer patient; guidelines provide standard of care for management of locally advanced rectal cancer (LARC) which is neoadjuvant concurrent modality of Chemo-Radio Therapy (CRT) followed by surgery including: Total Mesorectal Resection (TMR), then adjuvant chemotherapy [2] , but we still see variations in individual patient response and outcomes which prove that rectal cancer is still a heterogeneous disease.
Many researches were done to correlate the CRT sensitivity and response with multiple variables [3] . Microenvironment of the tumor and immune response of the host play an essential role in the sensitivity to CRT by proving that both the tumor infiltrating lymphocytes (TILs) density and peripheral blood circulating lymphocytes strongly correlate with the benefit rates to CRT in retrospective studies [4] .
The immune system enhances the removal of tumor cells and work for tumor progress control [5] . Previous studies have showed that immunologic response which exists pretreatment may enhance the efficacy of cancer treatment by chemotherapy and radiotherapy modalities [6] [7] [8] . High density of cytotoxic lymphocytes (CD8) in tumor tissue can kill tumor cells when it differentiates into effector cells and this is associated with decreased cancer dissemination and better outcomes [9] . In contrast, increase of infiltrating regulatory T cells (CD4) density, with its suppressor function to other effector T cell activities, is associated with poorer prognosis in some cancer types [10] [11]. If we detect factors which can predict response to treatment, we can avoid toxic useless modality of treatments and augment modalities for others, individualize our management, and predict oncological disease outcomes [12] .
In our study, we aim to assess the predictive value of peripheral lymphocytes, peripheral lymphocytes subsets, and tissue infiltrating lymphocytes (CD4 & CD8) by correlating to pathological response for post chemoradiotherapy in locally advanced rectal cancer and try for the first time to find correlation between peripheral lymphocyte subsets and tissue infiltrating lymphocytes (CD4 & CD8). Patients were immobilized in the prone position with a full bladder using a combination of a foam cushion and a prone head cushion. Setup marks were drawn on the patient's skin and the cushion after laser alignment. A planning CT scan was performed using a diagnostic CT scanner. The scan extended from the L2 vertebral body to 2 cm below the perineum, and axial images were obtained at 5 mm intervals and imported to the planning system. The 3D conformal RT was employed in the treatment of all patients involved in the analysis. RT planning was accomplished using a 4-field technique box technique the clinical tumor volume (CTV) included GTV plus a 2-cm margin and nodal drainage. At risk nodes include the presacral, pelvic mesentery, and internal iliac nodes. External iliac nodes included for T4 disease. A boost field included the initial GTV plus 2 cm and the sacral hollow. All the patients were irradiated on the linear accelerator, with high energy X-rays. Patients received a total dose of 50.4 Gy, Phase 1, 45 Gy in 25 fractions, followed by a Phase 2 boost of 5. 
Methods

Patients and Methods
This
 Laboratory methods
Before neoadjuvant CRT, we collected peripheral venous blood samples and 4 -6 weeks after completion of CRT from our study patients, 2 ml blood were collected in sterile EDTA vacutainer tube; the blood cell counts in the samples were analyzed by automated hematology analyzer (Sysmexxs 1000i manufactured in Japan). Flow cytometery was used to analyze lymphocyte subsets. The surface staining was done by adding 10 μl of each mAbs to 100 μl of anticoagulated blood in the same tube, incubation of tube was done in the dark, for 30 min at 4 ˚C, we did washing twice with FACS washing buffer. Lysing reagent was added to each tube, inverted once, kept for 3 minutes. Finally, 0.5 ml of Phosphate buffer saline (PBS) was added on the washed cells. Gating for the region of lymphocytes, and flow-cytometric analysis for each cell phenotype on 10,000 events was detected on the FACSCalibur flow cytometer (Becton Dickinson) using he Multiset software package (Becton Dickinson), and the CellQuest software was used for data analysis. We used a combination of isothiocyanate (FITC) and phycoerythrin (PE)-conjugated monoclonal antibody (Becton Dickinson, San Jose, CA, USA) to identify lymphocyte subsets, as follows: T lymphocyte: CD3(+)/CD19(−), B lymphocytes: CD3(−)/CD19(+), helper T lymphocytes (Th lymphocytes), CD3 (+)/CD4(+), cytotoxic T lymphocytes (Tc lymphocytes) CD3(+)/CD8(+) and for the natural killer cells: CD3(−)/CD56(+) as shown in Figure 1 [13] .  Routine Histopathological method Colonscopic biopsy samples which obtained from the 40 patients d before the start of CRT, fixed in 10% formalin solution, then put in paraffin, serial-step sections of the blocks were cut with 3 μm thickness, stained by routine hematoxylin & eosin stains and diagnosed in Pathology Department. Pathologic staging according to the seventh edition of the American Joint Committee on Cancer staging system (AJCC-7) classification was used [14] ; and for grading we depend on the World Health Organization (WHO) classification [15] . The T cells numbers and distribution in biopsy samples before CRT were assessed with immunohistochemical staining with Abs against CD4 and CD8, it was performed by streptavidin biotin technique as described by Hsu and Shinto [16] [17]. We incubated sections with primary rabbit polyclonal anti-CD8 antibody 
Statistical Analysis
Ethical Considerations
Informed consent was obtained from all participants included in the study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Results
Patient Characteristics
Our study included 40 patients with confirmed locally advanced rectal cancer, 26 (65%) of them were males and 14 (35%) were females with age range from 33 -70 median; 59.5 years. 33 (82.5%) cases were conventional adenocarcinoma and 7 (17.5%) cases were mucoid carcinoma. Pretreatment positive cN were seen in 75% of our patients (all details are presented in Table 1 ).
Clinical Results
There was a significant correlation between pretreatment clinical T & N and post treatment pathological T, pathological N (p-value 0.004 and 0.015 respectively). We did not found any significant correlation between any one of clinicopathological parameters and peripheral lymphocyte counts either pre or post CRT. Postsurgery, our patients divided into 2 groups depending on AJJC regression grade; high responders G0, 1 (Hi-R) achieved in 18 patients including 6 patients with CpCR (15%), and low responders G2, 3 (Lo-R) seen in 22 patients (55%). By using univariate analysis we found pretreatment age and clinical T were associated with good response (Hi-R) significantly (p-value 0.009 and 0.003 respectively) Table 2 .
For pre chemoradiotherapy counts of TLC, ANC, peripheral lymphocyte count and counts of lymphocytes subsets (T lymphocytes, Th, Tc) all showed higher median values in patients with high regression rate (Hi-R) compared to low regression (Lo-R) group as shown in Figure 2 (a). Figure 2 (b) also showed the same trend when comparing high regression to low regression group; median values for post chemo radiotherapy lab all were higher in high responders (Table 3) .
We found significant positive correlation between higher TLC, lymphocyte count, T lymphocytes, Th, Tc and regression rate for pre-CRT values, but for post CRT results we did not found any significant correlation with any of lymphocytes, or lymphocytes subsest Table 4 .
Immunohistochemical Results
CD4 expression: High expression of CD4 was detected in 19 (47.5%) patients & CD8 expressions showed statistically highly significant correlations with high regression rate (p < 0.01) ( Table 6 ). 
Discussion
Although the current multimodal treatment of locally advanced rectal cancer provided good results, we are still in need for patient-tailored treatments which expected to give greater benefit [19] . Denkert et al. [8] reported that there was significant effect for tumor infiltration of lymphocytes and achieving pCR in surgical specimens after neoadjuvant chemotherapy in breast cancer. Also a correlation between baseline peripheral lymphocyte counts and disease outcome in patients with other types of malignancies, including carcinoma of the uterine cervix and breast was reported [20] .
Kitayama et al. [21] found that circulating lymphocytes play an important part for achieving benefit of preoperative radiotherapy in locally advanced rectal cancer (LARC). In our study we found that a high pre-CRT total lymphocytes count in the peripheral blood of rectal cancer patients was significantly associated with pathological response and high regression rate, and this as reported by Kitayama et al., Choi [24] who failed to find significant correlation between baseline blood lymphocyte counts with pCR and he explained this because they excluded patients with baseline lymphopenia from their study populations before preoperative CRT. Lymphopenia initially and lymphopenia as treatment effect has a negative prognostic value in various settings and malignancies [25] It was previously demonstrated that the densities of CD4(+) and CD8(+) tumor-infiltrating lymphocytes (TIL) had significant association with the histological grade after CRT, also in achieving CR post CRT and the density of CD8(+)
TIL was found as an independent prognostic factor [31] . In our results, we detected a strong correlation between the density of CD4(+) and CD8(+) T cells in [34] . In contrary to that, Grabenbauer et al. [6] showed that in anal squamaous cell carcinoma tumor-infiltrating CD8(+) T cells, had an adverse prognostic effect on response to CRT. This may explained by the presence of human papilloma virus which is usually associated with anal carcinoma, it affect the histological characteristics of the tumor stroma by specific viral proteins processed in tumor cells.
Studies not investigate the relation between peripheral blood lymphocytes and tumor-infiltrating lymphocytes (TIL) in wide range. Milne et al. [35] failed to document correlation between the lymphocyte count in peripheral blood and CD8(+) or CD20(+) TIL in h ovarian cancer patients, he found significant correlation of both lymphocyte count and TIL with prognosis, but the correlations were independent of each other, but in our study we are the first to find correlation between the pre CRT peripheral lymphocytes subsets and tissue expression of CD4 & 8 in rectal cancer patients. We see significant positive correlation between pre CRT peripheral lymphocyte, T lymphocytes, Th, Tc and tissue CD4 & CD8 and all were statistically significant correlated to tumor regression rate.
Preoperative neoadjuvant therapy is not like adjuvant therapy, because it provides other short term endpoints based on pathologic tumor response. It is now documented that after preoperative CRT for rectal cancer patients who achieving pathologic complete response (ypCR) have favorable long-term outcomes [36] .
In our result, endpoints were limited to the pathologic regression but we can rely on the KROG 09-01 trial which concluded that post preoperative chemoradiotherapy in rectal cancer patients, those who gained pathological remission showed better disease outcomes. Kitayama et al. [5] showed that high lymphocyte count was associated significantly with better patients outcome regard overall and disease-free survival.
Conclusion
In conclusion, despite our study, small number of patients and short-term follow-up, we found that the pre-CRT peripheral lymphocytes count, peripheral 
